SEHK:2142Biotechs
Is HBM Holdings (SEHK:2142) Fully Valued After Its Asthma IND Approval?
HBM Holdings (SEHK:2142) is in focus after China’s National Medical Products Administration approved the Investigational New Drug application for HBM7575/SKB575, a long-acting bispecific antibody candidate for asthma co-developed with Kelun-Biotech.
See our latest analysis for HBM Holdings.
The IND approval appears to have reinforced interest in HBM Holdings, with the HK$11.96 share price supported by a 9.72% 1 month share price return and a very large 3 year total shareholder return, even...